
Survodutide Shows No Added Cardiovascular Risk in Trial of Patients With Obesity
A large randomized trial found that survodutide, an investigational drug that targets both the glucagon and GLP-1 receptors, was safe for adults with obesity who had established cardiovascular disease, chronic kidney disease, or an increased risk of cardiovascular disease. Among more than 5,500 patients, the rate of major cardiovascular events was 3.7% on survodutide and 4.1% on placebo, meeting the noninferiority standard. The results were presented at the American Heart Association annual meeting and published simultaneously in The Lancet. Investigators said the study shows cardiovascular harm can be ruled out, but it does not show cardiovascular benefit.










